Published in final edited form as:

Tetrahedron Asymmetry. 2008 December 12; 19(24): 2835–2838. doi:10.1016/j.tetasy.2008.12.013.

Concise syntheses of enantiomerically pure protected 4-hydroxypyroglutamic acid and 4-hydroxyproline from a nitroso-cyclopentadiene cycloadduct

Weiqiang Huang and Marvin J. Miller

Department of Chemistry & Biochemistry, University of Notre Dame, 251 Nieuwland Science Hall, Notre Dame, Indiana 46556, USA

Abstract

O-TBS-protected methyl *trans*-4-hydroxypyroglutamate and methyl *trans*-4-hydroxyproline ester were synthesized from nitroso-cyclopentadiene Diels-Alder cycloadducts. Enzymatic resolution of the key intermediate, 4-amino-cyclopent-2-enol, provides access to both L- and D- amino acids.

1. Introduction

Syntheses and studies of both non-proteinogenic natural and unnatural amino acids continue to be of considerable interest, often because of their enzyme inhibitory and antimetabolite properties. Among these amino acids, substituted glutamic acids attract particular attention because of their interaction with glutamate receptors in the central nervous system (CNS) and their involvement in many other biological processes.¹ Proline and its derivatives are of considerable interest because their cyclic structures play a critical role in forming protein and peptide secondary structures such as β -turns and α -helices.² 4-Substituted prolines are particularly interesting because the C-4 substituents can influence not only the conformation of the pyrrolidine ring, but also the rate of *cis-trans* isomerization about the amide bond. In the investigation of collagenous peptides that have repeating units of Gly-X-Y (X is often occupied by proline residues and Y is frequently occupied by hydroxyproline residues), hydroxylation of proline at the 4-position is found to affect greatly the conformational stability of the collagen triple helix.³ In addition, many biologically active natural products including kainic acid have a 4-substituted proline framework.⁴ Due to the biological importance of substituted glutamic acids and 4-substituted prolines, extensive efforts have focused on development of their syntheses. Among these studies, 4-hydroxypyroglutamates have received particular interest⁵ because they are able to be transformed to both 4-substituted glutamic acids and prolines. In addition, they also have been employed as key intermediates in the syntheses of many biologically interesting heterocycles.⁶ Herein, we report asymmetric syntheses of substituted pyroglutamate and proline derivatives from oxazines that are readily derived from nitroso cycloaddition reactions.

2. Results and discussion

Nitroso Diels-Alder reactions with 1,3-cycloalkadienes affords cycloadducts **2**. These versatile compounds have been used to synthesize many natural products and other biologically interesting compounds.⁷ The same scaffolds are readily converted to novel amino acids. Oxidative cleavage of the double bond of **2** gives cyclic oxyamino acids **3**. Subsequent N-O bond reduction provides the corresponding acyclic hydroxy α -amino acids **5** (Route A). Alternatively, N-O reduction of **2** gives amino hydroxy cycloalkenes **4** that can also be oxidatively converted to amino acids **5** (Route B). We anticipated that these intermediates could also serve as precursors of substituted pyroglutamates **6** and prolines **7**. Thus, we became interested in developing asymmetric syntheses of these useful amino acids.

Using generalized route A (Scheme 1), we previously reported specific examples of the syntheses of dipeptides such as **12**, that contain carboxy proline analogues and conformationally restricted glutamate analogs **3**. The method involved oxidation of amino acid hydroxamates **9** in the presence of dienes, to trap the transient nitroso agent **10** giving adduct **11** and subsequent alkene oxidation to generate **12**.^{7a} Diastereoselectivity of the cycloaddition (**10** $\rightarrow$ **11**) depended on the size of the starting amino acid side chain (R of **8**) and, using route B, enantiomerically enriched forms of **4** could be obtained by removal of the starting amino acid either hydrolytically or under Edman degradation conditions.^{7f} Addition of appropriate side chains, such as a phenylacetyl group (penicillin G side chain), imparted antibiotic activity, similar to that of β -lactam antibiotics, to amino acid **3**-containing peptides such as **13**.⁸ Heinz also used nitroso cycloaddition chemistry and a variant of route A to synthesize racemic 4-hydroxypyroglutamate **14** in a sequence that also included high pressure N-O bond reduction.^{5a}

While route A does provide access to novel amino acids and the use of amino acid hydroxamates **9** gives diastereoselectively enriched cycloadducts and eventual peptides, we sought alternative methods that would provide access to substituted glutamates, prolines and analogs in enantiomerically pure form. No catalytic asymmetric intermolecular acylnitroso cycloaddition reaction has yet been developed despite considerable effort⁹ although a moderately successful intramolecular example has been described.¹⁰ Yamamoto has reported very effective catalytic asymmetric cycloadditions using pyridyl nitroso agents, but removal of the pyridyl moiety requires several steps and is often low yielding.^{7c,d} Consequently, with a renewed focus on the potential of route B, we sought to capitalize on our previously reported enzymatic resolution of amino cyclopentenols **4**¹¹ to allow access to either enantiomer of the targeted glutamate and proline analogs. Thus, NaIO₄-mediated oxidation of Boc-hydroxylamine **15** in the presence of cyclopentadiene afforded cycloadduct **16**. Then, *N*-O reduction with 20 mol% of molybdenumhexacarbonyl in the presence of excess NaBH₄ gave ($\pm$)-aminocyclopentenol **17** in 60% overall yield from *N*-hydroxycarbamate **15**. Multigram kinetic resolution of **17** with immobilized *Candida antartica* lipase B (CALB) provided acetate (–)-**18** in 92–98% *ee* after 43% conversion (98% after one recrystallization) as well as (–)-**17** in 46% (98% *ee* after one recrystallization). Methanolysis of acetate **18** gave alcohol (+)-**17**.

Reaction of (+)-**17** with TBSCl gave silyl ether **19**, which was oxidized with RuCl₃/NaIO₄ to the diacid which upon treatment with excess diazomethane provided protected methyl *trans*-*N*-Boc-4-hydroxypyroglutamate **20** in moderate yield. The *R*-configuration of the α -amino acid carbon (C-2) in **20** was confirmed to correspond with that of D-glutamate by comparison to reported specific rotation data.^{5b}

Reduction of pyroglutamates to proline derivatives has been effected with BH₃·Me₂S¹² or NaBH(OMe)₃.¹³ While subjection of **20** to these conditions resulted in decomposition or no

desired product, we did find that a two-step process that proceeded through a hemiaminal intermediate was effective.¹⁴ Thus, treatment of **20** with LiEt₃BH at -78°C gave isolable hemiaminal **21** which upon reaction with BF₃·OEt₂ and Et₃SiH provided protected 4-hydroxyproline **22**.¹⁵ The NMR spectrum of **22** was consistent with that reported by Gellman.¹⁶

The methodology described here provides access to 4-substituted pyroglutamates and prolines from readily prepared 4-aminocyclopent-2-enols in 2 to 3 steps. The availability of both enantiomers of 4-aminocyclopent-2-enol via enzymatic resolution makes it feasible to synthesize both the L- and D- amino acids. Use of homologous or other dienes in the initial cycloaddition will allow syntheses of numerous analogs of potential interest.

3. Experimental

General

Tetrahydrofuran (THF) was distilled from sodium metal/benzophenone ketyl and methylene chloride was distilled from calcium hydride. All other solvents and chemicals were purchased from Acros or Aldrich and used as is. Silica gel flash column chromatography was performed using silica gel 60 (30–70 μm irregular particles). All specific rotations were measured using a Perkin Elmer model 343 polarimeter at 589 nm and 20°C. Proton (¹H NMR) and carbon (¹³C NMR) nuclear magnetic resonance spectra were recorded on a Varian UnityPlus 300 NMR at 300 MHz and 75 MHz, respectively. High resolution mass spectra were recorded on a JEOL JMS-AX505 HA Double Sector Mass Spectrometer.

4-(*tert*-Butyl-dimethyl-silanyloxy)-cyclopent-2-enyl]-carbamic acid *tert*-butyl ester **19**

To a solution of (+)-**17**¹¹ (243 mg, 1.22 mmol) in DMF (3 mL) was added TBDMSCl (276 mg, 1.83 mmol) and imidazole (249 mg, 3.66 mmol), and the mixture was stirred overnight at rt under N₂. DMF was removed *in vacuo*, and 20 mL of EtOAc was added to dissolve the residue. The EtOAc solution was washed with 5% Na₂CO₃ solution and brine, and then dried over Na₂SO₄. Removal of the Na₂SO₄ and solvent gave the title product as a light yellow oil (380 mg, 99%). [α]_D²⁰ -0.3 (c 1.0, CHCl₃), ¹H NMR (300 MHz, CDCl₃) δ : 5.80 (m, 2H), 4.69 (m, 2H), 4.57 (br, 1H), 2.70 (dt, *J*₁ = 13.5 Hz, *J*₂ = 8.4 Hz, 1H), 1.43 (s, 9H), 1.34 (dt, *J*₁ = 13.5 Hz, *J*₂ = 5.1 Hz, 1H), 0.89 (s, 9H), 0.07 (s, 6H); ¹³C NMR (75 MHz, CDCl₃) δ : 155.4, 136.7, 133.9, 79.5, 75.6, 54.5, 42.9, 28.6, 26.1, 18.4, -3.4, -4.5. HRMS Calculated for C₁₆H₃₂NO₃Si(M+H)⁺: 314.2151, Found: 314.2144.

4-(*tert*-Butyl-dimethyl-silanyloxy)-5-oxo-pyrrolidine-1,2-dicarboxylic acid 1-*tert*-butyl ester 2-methyl ester **20**

To a solution of **19** (157 mg, 0.5 mmol) in EtOAc/CH₃CN (1:1, 2.8 mL) at 0°C was added NaIO₄ (481 mg, 2.25 mmol) in H₂O (5.5 mL) followed by RuCl₃ (18.4 mg, 0.0885 mmol). The mixture was stirred at 0°C open to the air for 15 min and then at room temperature for 2 h. The reaction mixture was suction filtered through a short pad of Celite®. The layers were separated, and the aqueous layer was saturated with NaCl and extracted with EtOAc (3×3 mL). The combined organic extracts were dried over MgSO₄, filtered, and concentrated to give the crude diacid as a brown oil.

The brown oil was dissolved in Et₂O (8.0 mL) and treated with excess CH₂N₂ in Et₂O at -78 °C. After 30 min, the excess CH₂N₂ was quenched with AcOH in Et₂O. The reaction mixture was washed with saturated NaHCO₃ solution. The aqueous layer was extracted with Et₂O (1×8 mL). The combined organic layers were then dried (MgSO₄), filtered, and concentrated to give a brown oil that was chromatographed on silica gel eluting with EtOAc/hexanes (1:6–1:3) to give compound **20** (82 mg, 44%) as a clear oil. [α]_D²⁰ = -34.7 (c 1.0, CHCl₃), ¹H NMR (300

MHz, CDCl₃), δ : 4.59 (dd, $J_1 = 9.6$ Hz, $J_2 = 1.5$ Hz, 1H), 4.42 (dd, $J_1 = 10.2$ Hz, $J_2 = 8.1$ Hz, 1H), 3.79 (s, 3H), 2.37 (ddd, $J_1 = 13.2$ Hz, $J_2 = 8.4$ Hz, $J_3 = 1.5$ Hz, 1H), 2.21 (dt, $J_1 = 13.2$ Hz, $J_2 = 10.2$ Hz, 1H), 1.50 (s, 9H), 0.89 (s, 9H), 0.18 (s, 3H), 0.13 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ : 172.2, 171.9, 149.7, 84.0, 69.8, 55.1, 52.9, 32.0, 28.0, 25.8, 18.4, -4.3, -5.1. HRMS Calculated for C₁₇H₃₂NO₆Si (M+H)⁺: 374.1999, Found: 374.1972.

4-(*tert*-Butyl-dimethyl-silanyloxy)-pyrrolidine-1,2-dicarboxylic acid 1-*tert*-butyl ester 2-methyl ester **22**

A 1.0 M solution of lithium triethylborohydride in THF (0.225 mL, 0.225 mmol) was added to a solution of **20** (70 mg, 0.187 mmol) in THF (4 mL) at -78°C under a nitrogen atmosphere. After 30 min, the reaction mixture was quenched with saturated aqueous NaHCO₃ (0.35 mL) and warmed to 0°C. H₂O₂ (30%) (1 drop) was added and the mixture was stirred at 0°C for 20 min. The organic solvent was removed *in vacuo*, and the aqueous layer was extracted with CH₂Cl₂ (3×5 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated. The crude product **21** (78 mg) was used without further purification.

A solution of **21** and triethylsilane (0.030 mL, 0.187 mmol) in CH₂Cl₂ (3 mL) was cooled to -78°C and boron trifluoride etherate (0.026 mL, 0.206 mmol) was then added dropwise under a nitrogen atmosphere. After 30 min, 0.030 mL of triethylsilane and 0.026 mL of boron trifluoride etherate were added. The resulting mixture was stirred for 2 h at -78°C and was then quenched with saturated aqueous NaHCO₃ (0.3 mL). The mixture was extracted with CH₂Cl₂ (3×5 mL), dried over Na₂SO₄ and filtered. Evaporation of the solvent and purification by flash chromatography (EtOAc/hexanes: 10–30%) gave 42 mg (63%) of product **22** as a clear oil. $[\alpha]_D^{20} = +39.2$ (c 1.0, CHCl₃), ¹H NMR (300 MHz, CDCl₃) δ : 4.41 (m, 1H), 4.33 (t, $J = 7.8$ Hz, 1H), 3.73 (s, 3H), 3.59 (td, $J_1 = 10.5$ Hz, $J_2 = 4.8$ Hz, 1H), 3.34 (m, 1H), 2.17 (m, 1H), 2.02 (m, 1H), 1.46–1.41 (d, 9H), 0.87 (s, 9H), 0.06 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) mixture of rotamers δ : 174.0, 173.8, 154.8, 154.1, 80.3, 70.6, 69.9, 58.3, 57.8, 55.1, 54.8, 52.4, 52.2, 40.0, 39.1, 28.6, 28.5, 25.9, 18.2, 1.22, -4.6, -4.7. HRMS Calculated for C₁₇H₃₄NO₅Si (M+H)⁺: 360.2206, Found: 360.2203.

Acknowledgments

This work was supported by grants from the National Institutes of Health (GM 68012 and GM 075855). We gratefully acknowledge the Lizzadro Magnetic Resonance Research Center at Notre Dame for NMR facilities and Nonka Sevova for mass spectrometry data. Special thanks are given to Baiyuan Yang.

References and notes

- (a) McDonald JW, Johnston MV. Brain Res Rev 1990;15:41. [PubMed: 2163714] (b) Collingridge GL, Lester RA. Pharmacol Rev 1989;41:143. [PubMed: 2558391]
- (a) Sibanda BL, Blundell TL, Thornton JM. J Mol Biol 1989;206:759. [PubMed: 2500530] (b) Barlow DJ, Thornton JM. J Mol Biol 1988;201:601. [PubMed: 3418712] (c) Rose GD, Gierasch LM, Smith JA. Adv Protein Chem 1985;37:1. [PubMed: 2865874]
- (a) Berg RA, Prockop DJ. Biochem Biophys Res Commun 1973;52:115–120. [PubMed: 4712181] (b) Improtta R, Benzi C, Barone V. J Am Chem Soc 2001;123:12568–12577. [PubMed: 11741421] (c) Improtta R, Mele F, Crescenzi O, Benzi C, Barone V. J Am Chem Soc 2002;124:7857–7865. [PubMed: 12083941] (d) DeRider ML, Wilkens SJ, Waddell MJ, Bretscher LE, Weinhold F, Raines RT, Markley JL. J Am Chem Soc 2002;124:2497–2505. [PubMed: 11890798]
- (a) Maeda M, Kodama T, Tanaka T, Yoshizumi H, Takemoto T, Nomoto K, Fujita T. Chem Pharm Bull 1986;34:4892–4895. (b) Takemoto T, Daigo K. Chem Pharm Bull 1958;6:578–580. (c) Clayden J, Menet CJ, Tchabanenko K. Tetrahedron 2002;58:4727–4733.
- (a) Heinz L, Lunn WHW, Murff RE, Paschal JW, Spangle LA. J Org Chem 1996;61:4838–4841. [PubMed: 11667426] (b) Merino P, Anoro S, Franco S, Merchan FL, Tejero T, Tunon V. J Org Chem 2000;65:1590–1596. [PubMed: 10814132]

6. (a) Despinoy XLM, McNab H. *Tetrahedron* 2000;56:6359–6383. (b) Najera C, Miguel Y. *Tetrahedron: Asymmetry* 1999;10:2245–2303.
7. (a) Vogt PF, Miller MJ. *Tetrahedron* 1998;54:1317–1348. (b) Iwasa S, Fakhruddin A, Nishiyama H. *Mini-Rev Org Chem* 2005;2:157–175. (c) Yamamoto H, Momiyama N. *Chem Comm* 2005:3514–3525. [PubMed: 16010311] (d) Yamamoto Y, Yamamoto H. *Eur J Org Chem* 2006:2031–2043. (e) D'Andrea S, Zheng ZB, DenBleyker K, Fung-Tomc JC, Yang H, Clark J, Taylor D, Bronson J. *Bioorg Med Chem Lett* 2005;15:2834–2839. [PubMed: 15911264] (f) Ritter AR, Miller MJ. *Tetrahedron Lett* 1994;35:9379–9382. (g) Shireman BT, Miller MJ. *J Org Chem* 2001;66:4809–4813. [PubMed: 11442409] (h) Zhang D, Suling C, Miller MJ. *J Org Chem* 1998;63:885–888. [PubMed: 11672089] (i) Mulvihill MJ, Surman MD, Miller MJ. *J Org Chem* 1998;63:4874–4875. (j) Surman MD, Miller MJ. *J Org Chem* 2001;66:2466–2469. [PubMed: 11281789] (k) Surman MD, Mulvihill MJ, Miller MJ. *J Org Chem* 2002;67:4115–4121. [PubMed: 12054945] (l) Lee W, Kim K-H, Surman MD, Miller MJ. *J Org Chem* 2003;68:139–149. [PubMed: 12515472] (m) Hudlicky T, Rinner U, Gonzalez D, Akgun H, Schilling S, Siengalewicz P, Martinot TA, Pettit GR. *J Org Chem* 2002;67:8726–8743. [PubMed: 12467383] (n) Sato T, Aoyagi S, Kibayashi C. *Org Lett* 2003;5:3839–3842. [PubMed: 14535723] (o) Behr J, Chevrier C, Defoin A, Tarnus C, Streith J. *Tetrahedron* 2003;59:543–553. (p) Mineno T, Miller MJ. *J Org Chem* 2003;68:6591–6596. [PubMed: 12919021] (q) Lee W, Miller MJ. *J Org Chem* 2004;69:4516–4519. [PubMed: 15202910] (r) Surman MD, Mulvihill MJ, Miller MJ. *Org Lett* 2002;4:139–141. [PubMed: 11772110] (s) Baldwin JE, Aldous DJ, Chan C, Harwood LM, O'Neil IA, Peach JM. *Synlett* 1989:9–14. (t) Baldwin JED, Bailey P, Gallacher G, Otsuka M, Singleton KA, Wallace PM, Prout K, Wolf WM. *Tetrahedron* 1984;40:3695–3708. (u) Keck GE, Fleming SA. *Tetrahedron Lett* 1978;19:4763–4766. (v) Streith J, Defoin A. *Synthesis* 1994:1107–1117. (w) Defoin A, Fritz H, Geffroy G, Streith J. *Tetrahedron Lett* 1986;27:4727–4730. (x) Boger DL, Patel M, Takusagawa F. *J Org Chem* 1985;50:1911–1916. (y) O'Bannon PE, Sulze D, Schwarz H. *Helv Chim Acta* 1991;74:2068–2072. (z) Dao LH, Dust JM, Mackay D, Watson KN. *Can J Chem* 1979;57:1172–1179. (aa) Martin SF, Hartmann M, Josey JA. *Tetrahedron Lett* 1992;33:3583–3586. (bb) Lin C, Wang Y, Hsu J, Chiang C, Su D, Yan T. *J Org Chem* 1997;62:3806–3807. (cc) Gouverneur V, Dive G, Ghosez L. *Tetrahedron: Asymmetry* 1991;2:1173–1176. (dd) Gouverneur V, Ghosez L. *Tetrahedron: Asymmetry* 1990;1:363–366. (de) Strieth J, Defoin A. *Synlett* 1996:189–200. (ee) Cardillo B, Galeazzi R, Mobbili G, Orena M, Rossetti M. *Tetrahedron Asymmetry* 1994;5:1535–1540. (ff) Miller A, Procter G. *Tetrahedron Lett* 1990;31:1041–1042. (gg) Miller A, Procter G. *Tetrahedron Lett* 1990;31:1043–1046. (hh) Miller A, Paterson TM, Procter G. *Synlett* 1989:32–34. (ii) King SB, Ganem B. *J Am Chem Soc* 1994;116:562–570. (jj) Muxworthy JP, Wilkinson JA, Procter G. *Tetrahedron Lett* 1995;36:7535–7538. (kk) Muxworthy JP, Wilkinson JA, Procter G. *Tetrahedron Lett* 1995;36:7539–7540. (ll) Muxworthy JP, Wilkinson JA, Procter G. *Tetrahedron Lett* 1995;36:7541–7544. (mm) Kirby GW, Nazeer M. *Tetrahedron Lett* 1988;29:6173–6174. (nn) Kirby GW, Nazeer M. *J Chem Soc, Perkin Trans 1: Org Bio-Org Chem* 1993:1397–1402.
8. Nora GP, Miller MJ, Mollmann U. *Bioorg Med Chem Lett* 2006;16:3966–3970. [PubMed: 16730172]
9. Howard JAK, Ilyshenko G, Sparkes HA, Whiting A. *Dalton Trans* 2007:2108–2111. [PubMed: 17514329]
10. Chow CP, Shea KJ. *J Am Chem Soc* 2005;127:3678–3679. [PubMed: 15771485]
11. (a) Mulvihill MJ, Gage JL, Miller MJ. *J Org Chem* 1998;63:3357–3363. (b) Li FZ, Brogan JB, Gage JL, Zhang DY, Miller MJ. *J Org Chem* 2004;69:4538–4540. [PubMed: 15202916]
12. (a) Rodriguez M, Terracciano S, Cini E, Settembrini G, Bruno I, Bifulco G, Taddei M, Gomez-Paloma L. *Angew Chem Int Ed* 2006;45:423–427. (b) Barraclough P, Dieterich P, Spray CA, Young DW. *Org Biomol Chem* 2006;4:1483–1491. [PubMed: 16604215]
13. Clayden J, Tchabanenko K. *Chem Commun* 2000:317–318.
14. Clayden J, Knowles FE, Baldwin IR. *J Am Chem Soc* 2005;127:2412–2413. [PubMed: 15724994]
15. Pedregal C, Ezquerro J, Escribano A, Carreno MC, Garcia RJL. *Tetrahedron Lett* 1994;35:2053–2056.
16. Huck BR, Gellman SH. *J Org Chem* 2005;70:3353–3362. [PubMed: 15844969]

Scheme 1.

Generalized nitroso cycloaddition followed by elaboration to novel amino acids.

Scheme 2.

Cycloadditions of amino acid-based acylnitroso agents gives precursors to novel peptides and antibiotics.

Scheme 3.

Enzymatic resolution of racemic aminoalcohols obtained from nitroso cycloadducts provides enantiomerically pure amino cyclopentols.

Scheme 4.
Conversion of aminocyclopentenol, **17**, to pyroglutamate **20**.

Scheme 5. Conversion of pyroglutamate, **20**, to proline derivative, **22**.